Eli Lilly (LLY) says next-gen weight loss drug, retatrutide beat Ozempic on weight loss and A1C reduction in a head-to-head Phase 3 trial for diabetes. Read more here.
CryptoAlerta — análise de criptomoedas e mercado em tempo real